The Role of Nanoparticle Morphology on Enhancing Delivery of Budesonide for Treatment of Inflammatory Bowel Disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Chemical Society Country of Publication: United States NLM ID: 101504991 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1944-8252 (Electronic) Linking ISSN: 19448244 NLM ISO Abbreviation: ACS Appl Mater Interfaces Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, D.C. : American Chemical Society
    • Subject Terms:
      Budesonide*/chemistry ; Budesonide*/administration & dosage ; Budesonide*/therapeutic use ; Budesonide*/pharmacokinetics ; Nanoparticles*/chemistry ; Nanoparticles*/therapeutic use ; Silicon Dioxide*/chemistry ; Inflammatory Bowel Diseases*/drug therapy ; Inflammatory Bowel Diseases*/pathology ; Drug Carriers*/chemistry; Animals ; Mice ; Polymethacrylic Acids/chemistry ; Drug Liberation ; Humans ; Anti-Inflammatory Agents/chemistry ; Anti-Inflammatory Agents/therapeutic use ; Anti-Inflammatory Agents/administration & dosage ; Porosity ; Hydrogen-Ion Concentration
    • Abstract:
      Inflammatory bowel disease (IBD) is a chronic and recurrent inflammatory disease that affects the gastrointestinal tract. The major hurdles impeding IBD treatment are the low targeting efficiency and short retention time of drugs in IBD sites. Nanoparticles with specific shapes have demonstrated the ability to improve mucus retention and cellular uptake. Herein, mesoporous silica nanoparticles (MSNs) with various morphologies were used to deliver budesonide (BUD) for the treatment of IBD. The therapeutic efficacy is strongly dependent on their shapes. The system comprises different shapes of MSNs as carriers for budesonide (BUD), along with Eudragit S100 as the enteric release shell. The encapsulation of Eudragit S100 not only improved the stability of MSNs-BUD in the gastrointestinal tract but also conferred pH-responsive drug release properties. Then, MSNs efficiently deliver BUD to the colon site, and the special shape of MSNs plays a critical role in enhancing their permeability and retention in the mucus layer. Among them, dendritic MSNs (MSND) effectively reduced myeloperoxidase (MPO) activity and levels of inflammatory cytokines in the colon due to long retention time and rapid release in IBD sites, thereby enhancing the therapeutic efficacy against colitis. Given the special shapes of MSNs and pH-responsivity of Eudragit S100, BUD loaded in the voids of MSND (E@MSNs-BUD) could penetrate the mucous layer and be accurately delivered to the colon with minor side effects. This system is expected to complement current treatment strategies for the IBD.
    • Contributed Indexing:
      Keywords: IBD; MSNs; budesonide; colon target; oral
    • Accession Number:
      51333-22-3 (Budesonide)
      7631-86-9 (Silicon Dioxide)
      0 (Drug Carriers)
      25086-15-1 (methylmethacrylate-methacrylic acid copolymer)
      0 (Polymethacrylic Acids)
      0 (Anti-Inflammatory Agents)
    • Publication Date:
      Date Created: 20240618 Date Completed: 20240704 Latest Revision: 20240704
    • Publication Date:
      20240704
    • Accession Number:
      10.1021/acsami.4c05214
    • Accession Number:
      38888094